title: Micronucleated erythrocytes in newborn rats exposed to raltegravir placental transfer.
abstract: The use of raltegravir in treating HIV/AIDS has been proposed due to its effectiveness in suppressing high loads of HIV RNA in pregnant women, thus preventing infection of the fetus. However, administration of raltegravir during pregnancy produces a compound which is transferred to high concentrations to the offspring. The objective of this study is to evaluate the transplacental genotoxic effect of raltegravir in newborn rats. We evaluated the number of micronucleated erythrocytes (MNE), micronucleated polychromatic erythrocytes (MNPCE), and polychromatic erythrocytes (PCE) in the peripheral blood samples of the offspring of Wistar rats treated 6 days before birth with oral administration of raltegravir. The animals were randomly assigned to five groups as follows: raltegravir at doses of 15, 30, or 60 mg/day, cyclophosphamide 10 mg/kg (positive control), or 0.5 ml of sterile water (negative control). In addition, the effect of these drugs on the weight and height of newborns was assessed. There were no differences in the number of MNE, MNPCE, and PCE, and a slight decrease in the weight and height was observed in the offspring of the rat mothers treated with raltegravir. Genotoxicity studies are required in pregnant women to determine the risk of using raltegravir to the fetuses.
authors: División de Neurociencias, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, 44340 Guadalajara, JAL, Mexico ; Departamento de Clínicas Médicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44350 Guadalajara, JAL, Mexico.
authors: Blanca Miriam
authors: BM
authors: Torres-Mendoza
authors: División de Neurociencias, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, 44340 Guadalajara, JAL, Mexico ; Maestría en Nutrición Clínica, Universidad del Valle de Atemajac, 45050 Zapopan, JAL, Mexico.
authors: Damharis Elizabeth
authors: DE
authors: Coronado-Medina
authors: Departamento de Biología Molecular y Genómica, Centro Universitario de Ciencias de la Salud, Instituto de Biología Molecular en Medicina y Terapia Génica, Universidad de Guadalajara, 44350 Guadalajara, JAL, Mexico.
authors: Belinda Claudia
authors: 0000-0003-2774-6390
authors: BC
authors: Gómez-Meda
authors: Unidad Médica de Alta Especialidad, Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, 44340 Guadalajara, JAL, Mexico.
authors: Eduardo
authors: E
authors: Vázquez-Valls
authors: Departamento de Clínicas Odontológicas Integrales, Centro Universitario de Ciencias de la Salud, Instituto de Investigación en Odontología, Universidad de Guadalajara, 44350 Guadalajara, JAL, Mexico.
authors: Ana Lourdes
authors: AL
authors: Zamora-Perez
authors: Departamento de Neonatología, Unidad Médica de Alta Especialidad, Hospital de Pediatría, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, 44340 Guadalajara, JAL, Mexico.
authors: María de Lourdes
authors: Mde L
authors: Lemus-Varela
authors: Laboratorio de Mutagénesis, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Sierra Mojada 800, Colonia Independencia, 44340 Guadalajara, JAL, Mexico.
authors: Guillermo Moisés
authors: 0000-0003-1257-4637
authors: GM
authors: Zúñiga-González
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000831:Animals, Newborn; D000998:Antiviral Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000633:toxicity; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D004912:Erythrocytes / Q000187:drug effects* / Q000502:physiology*; D005260:Female; D048629:Micronuclei, Chromosome-Defective / Q000139:chemically induced*; D010920:Placenta / Q000378:metabolism; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects / Q000097:blood / Q000139:chemically induced*; D011760:Pyrrolidinones / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000633:toxicity*; D000068898:Raltegravir Potassium; D051381:Rats; D017208:Rats, Wistar
chemical_list: D000998:Antiviral Agents; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium